Article Text

Download PDFPDF
Funding sought for further development of African horse sickness vaccine

Statistics from

RESEARCHERS at the Pirbright Institute say that they are confident that they have identified a safe and effective vaccination strategy against African horse sickness (AHS) virus that overcomes the drawbacks associated with current vaccines. They are now seeking to build a business case for their new strategy to encourage a manufacturer to develop it and bring it to market.

Although vaccines against AHS virus are already available, the researchers explain that these use live attenuated virus and are therefore not considered to be safe enough to be licensed for use in countries where AHS virus is not present; this includes the European Union. This, they say, can have a major negative impact on the equine industry and sport due to strict international travel controls to and from endemic countries. …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.